A Phase 4 interventional study of Elonva and Puregon in Infertility, sponsored by Eugonia. Status unknown at 1 site in Greece. Open to female participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-06-22.
Sponsored by Eugonia · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies testing corifollitropin alfa in Infertility — 1 open to participants now, 1 under way, none of them phase 3. corifollitropin alfa · Infertility.
Among the 26 studies testing corifollitropin alfa in Infertility, this one is the 16th largest by planned enrollment, is one of 3 that started in 2015, is one of 10 in phase 4, and was the 22nd registered.
2,090 studies on the registry are indexed under Infertility; 356 are open to participants now.
Browse Infertility studies →1 of the 26 studies testing corifollitropin alfa in Infertility is open now, in 1 country. Recruiting first, the newest first:
Instituto Valenciano de Infertilidad, IVI VALENCIA · Sites in Spain
Ages 18–35 · Women only
By country, each count listing its studies:
corifollitropin alfa: first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 233 Infertility studies recruiting now, 43 (18%) set no upper age limit and 184 (79%) stop at 75 or younger; 27 take children under 18; 74 take healthy volunteers.
This study: 18 Years to 40 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 6 · Phase 3 8 · Phase 4 10
First in 2000; this study’s year is marked. 3 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 62 is below the median of 134 across 1,415 interventional studies indexed under Infertility.
Median enrollment 90 across the 26 interventional studies. Of the 21 that completed or were terminated, 6 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 26 have an industry lead sponsor. The 10 most frequent:
Eugonia is the lead sponsor of 16 studies on the registry; none are open to participants now.
13 studies in Infertility by Eugonia: none open now, none under way, none of them phase 3. Of 7 finished, 0 (0%) have results posted.
Among the 13 studies in Infertility by Eugonia, this one is the 6th largest by planned enrollment of the 10 interventional ones that give a count, is the only one that started in 2015, is one of 5 in phase 4, and was the 8th registered.
Eugonia’s Infertility studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 26 studies testing corifollitropin alfa in Infertility, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eugonia’s 13 in Infertility:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this randomized controlled trial (RCT) is to compare a single injection of corifollitropin-alfa versus daily injections of follitropin beta regarding the number of oocytes retrieved, hormonal profile and follicle development in patients with high response undergoing ovarian stimulation for in vitro fertilization treatment using a gonadotropin-releasing hormone (GnRH) antagonist protocol combined with GnRH agonist trigger and cryopreservation of all embryos.
Corifollitropin alfa, a novel fusion protein lacking luteinizing hormone (LH) activity, has a longer elimination half-life and extended time to peak levels than recombinant follicle stimulating hormone (rFSH). A single injection of corifollitropin alfa may replace seven daily injections follitropin beta during the first week of ovarian stimulation, reducing patient discomfort.
The purpose of this RCT is to compare a single injection of corifollitropin-alfa versus daily injections of follitropin beta regarding the number of oocytes retrieved, as well as hormonal profile and follicle development in patients with high response undergoing ovarian stimulation for IVF using a GnRH antagonist protocol. In addition, incidence of unexpected ovarian hyperstimulation syndrome (OHSS) will be evaluated, although it is anticipated that GnRH agonist triggering will eliminate occurrence of the syndrome.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients will undergo ovarian stimulation using daily injections of recombinant FSH (Puregon), as performed traditionally in IVF cycles
Drug: Puregon
Patients will undergo ovarian stimulation using a single injection of corifollitropin alfa (Elonva)
Drug: Elonva
corifollitropin alfa (Elonva): a single injection 100 or 150 ug (depending on patient body weight) on Day 2/3 of menstrual cycle
Also known as: corifollitropin alfa
follitropin beta (Puregon): daily injections 150 IU from Day 2/3 of menstrual cycle until adequate follicle development is achieved
Also known as: follitropin beta
Number of oocytes retrieved
Time frame: Day of oocyte retrieval (Day 0)
Incidence of severe OHSS
Time frame: up to 5 days post oocyte retrieval
Follicle development
Time frame: Day of triggering final oocyte maturation = last day of ovarian stimulation (Day -2 prior to oocyte retrieval)
Fertilization rate
Time frame: Day 1 after oocyte retrieval
Blastocyst formation rates
Time frame: Day 5/6 after oocyte retrieval
Number of blastocysts cryopreserved
Time frame: Day 5/6 after oocyte retrieval
The record gives a start of Sep 2015, a primary completion of Sep 2016 and a completion of Dec 2016. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Corifollitropin alfa
Eugonia